Preoperative Management of Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Rangole, Ashvin; Bhatt, Aditi; Nikhilesh, Jain

doi:10.1007/s13193-016-0517-1

Cited by 3 publications

(1 citation statement)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior extensive surgical treatment is associated with delayed CRS/HIPEC and worse progression-free and overall survival for patients with appendiceal mucinous adenocarcinoma. However, no benefit has been found when using PSS for CRC [ 48 , 49 , 50 ].…”

Section: Prognostic Indicatorsmentioning

confidence: 99%

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies

Harper

Kim

Pandalai

2022

JCM

View full text Add to dashboard Cite

Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies.

show abstract

Section: Prognostic Indicatorsmentioning

confidence: 99%